was admitted to a locked facility due to inappropriate aggression. Two subjects became more agitated; one, more depressed.
There were small but significant post-treatment reductions for mean total MMSE scores 12.7 to 11.8; (p < 0.05) and total NPI scores 38.8 to 27.4; (p < 0.01) based on LOCF, with similar results for the completers (Total MMSE, p < 0.05; Total NPI, p = 0.03), and the delusions subscale of the NPI (p = 0.03) (see Table 1 published online at www.journals.cambridge.org/jid IPG).
The median levetiracetam dose for completers was 2000 mg qd (range = 625-2000 mg). Side-effects included lethargy/fatigue (5), increased agitation/ irritability (4), dizziness (2), decreased appetite (1), diarrhea (1), insomnia (1), and vivid dreams (1). Of the 19 who received at least one dose, 12 were receiving 1-3 psychotropic drugs, including SSRIs (6), lorazepam (5), trazodone (2), and neuroleptics (4). Of the five persons who received study drug alone; one had increased agitation and one developed lethargy.
In summary, we found frequent side-effects and possibly impaired cognition without great therapeutic efficacy. About six months after study completion, a patient who had continued on levetiracetam 500 mg bid suffered a generalized seizure following abrupt drug cessation, suggesting that if used, the drug should be withdrawn gradually.
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The transcobalamin 776C>G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease Accumulating evidence suggest that low vitamin B 12 status is associated with an increased risk of Alzheimer's disease (AD) (Refsum and Smith, 2003) . Transcobalamin (TC) binds vitamin B 12 (cobalamin) in plasma and is the critical transporter that delivers vitamin B 12 to peripheral tissues and the brain. Polyacrylamide gel electrophoresis reveals two common isotypes of TC, M and X, and also two rare variants, S and F. The main genetic determinant of this phenotypic variability is a C-to-G transition at position 776 in relation to the first nucleotide ( + 1) of the ATG-translation initiation codon in the TC gene, which leads to a substitution of arginine for proline at amino acid 259 of TC (Zetterberg et al., 2003a) . The vast majority of individuals with the wild-type homozygous 776CC genotype (proline/proline) have the TC M phenotype, while most 776GG (arginine/arginine) individuals have the X phenotype.
We have shown that the TC 776G allele is strongly associated with lower levels of holo-TC (the vitamin B 12 -TC complex) in cerebrospinal fluid (CSF) in patients with AD, in spite of normal vitamin levels in peripheral blood (Zetterberg et al., 2003b) . This indicates that holo-TC encoded by the 776G allele might cross the blood-brain barrier less efficiently or be less stable in CSF and, hence, less efficient with regards to delivering vitamin B 12 to the brain than 776C-encoded holo-TC. Moreover, we recently showed that the 776G allele is associated with earlier age of onset of AD (McCaddon et al., 2004) . Taken together, these findings suggest that improving the vitamin B 12 status of the elderly population by supplementation might postpone the development of AD in TC 776G homozygous and heterozygous individuals. It is, however, unknown if oral vitamin B 12 treatment improves the B 12 status in the central nervous system of these genotype carriers. Here, we determine the effect of oral vitamin B 12 treatment on holo-TC concentration in CSF in AD patients carrying the 776G allele.
Among outpatients being evaluated for cognitive dysfunction at the Neuropsychiatric Clinic, Malmö University Hospital, we selected 29 individuals (7 men, 22 women) who were on long-term oral vitamin B 12 treatment (1 mg daily). All underwent a thorough clinical examination and fulfilled the DSM-IV criteria for primary degenerative dementia of Alzheimer-type and NINCDS-ADRDA criteria for probable AD. The patients' mean age at disease onset (SD) was 75 (7.5) years. The study was approved by the Ethics Committee at the Malmö University Hospital and written informed consent was obtained from all patients or their closest relatives if a patient could not give valid consent.
Genotyping of the TC 776C>G polymorphism was performed using a solid-phase minisequencing technique (Zetterberg et al., 2003b) . Plasma total vitamin B 12 was determined by a commercial method (Bayer Corporation) on a Beckman-Coulter instrument. CSF holo-TC was analyzed in parallel with the previously reported measurements of holo-TC in patients without B 12 treatment by ELISA (Zetterberg et al., 2003b; Nexo et al., 2002) . Analytical imprecision was <10%.
As expected, median vitamin B 12 concentration (range) among the 29 vitamin B 12 -treated patients was high, 639 (129-1480) pmol/L. Only three of these individuals had the wild-type homozygous TC 776CC genotype (10%). Nineteen individuals (66%) had the heterozygous 776CG genotype and seven (24%) had the homozygous 776GG genotype. Median holo-TC concentration (range) in CSF was 60.0 (57.0-66.0) pmol/L in individuals with the 776CC genotype, 63.0 (18.0-162) pmol/L in individuals with the 776CG genotype and 48.0 (24.0-138) pmol/L in individuals with the 776GG genotype. These concentrations are well above the previously reported levels found in wild-type homozygous (776CC) individuals without oral vitamin B 12 treatment [30.0 (12.0-54.0) pmol/L] (Zetterberg et al., 2003b) . There was no detectable negative influence of the 776G allele on holo-TC concentration, although a slight effect of the 776G-allele may have been missed due to the restricted sample size. Nevertheless, these data show that oral vitamin B 12 treatment is associated with higher overall levels of holo-TC concentration in CSF also in individuals with the hypotranscobalaminemia-associated TC 776CG and 776GG genotypes.
In conclusion, the TC 776C>G polymorphism seems to be a modifiable genetic risk factor for vitamin B 12 deficiency in the brain. Since the 776G allele is associated with earlier age of onset of AD (McCaddon et al., 2004) , our results warrant additional investigations addressing whether it is possible to delay the development of AD in individuals with 776CG and 776GG genotypes by highdose oral vitamin B 12 supplementation.
